key: cord-1052278-shgu7pzg authors: Piccolo, V.; Bassi, A.; Argenziano, G.; Mazzatenta, C.; Cutrone, M.; Neri, I.; Grimalt, R.; Russo, T. title: Contemporary occurrence of Chilblain‐like lesions and Pityriasis rosea during the COVID‐19 pandemic date: 2021-06-07 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.17409 sha: de4d6c5e5c0ad2d63c3fadd95f5c1af59478f707 doc_id: 1052278 cord_uid: shgu7pzg During the second wave of infection, we came across an otherwise healthy 12-year-old girl with a 3-week history of erythematous-edematous and ulcerated lesions of the toes (Figure 1), compatible with the diagnosis of CLL. Similar lesions already appeared during the first wave of March-April 2020 and resolved spontaneously in 3 months. Apart from CLL, the patient contemporarily developed a classical mildly itchy pityriasis rosea (PR) on the trunk (Figure 2), that was the major reason of complaint in this occasion. The occurrence of chilblain-like lesions (CLL) has widely been described in literature during the two waves of COVID-19 pandemic and their association with SARS-CoV-2 infection has been thoroughly discussed. [1] [2] [3] [4] [5] [6] During the second wave of infection, we came across an otherwise healthy 12-year-old girl with a 3-week history of erythematous-oedematous and ulcerated lesions of the toes (Fig. 1) , compatible with the diagnosis of CLL. Similar lesions already appeared during the first wave of March-April 2020 and resolved spontaneously in 3 months. Apart from CLL, the patient contemporarily developed a classical mildly itchy pityriasis rosea (PR) on the trunk (Fig. 2 ) that was the major reason of complaint in this occasion. Full investigation about COVID status, including nasalpharyngeal swab and serology, was obtained with negative results. All the other blood examinations were normal. Family history was negative for cases of COVID-19. The patient was reassured, treated with anti-histamines for pruritus and she is now in follow-up for monitoring the evolution of cutaneous diseases. In the 'mare magnum' of cutaneous manifestations reported during the COVID-19 pandemic, definitely CLL represent the most representative and quite repetitive as they usually affect healthy adolescents with no or mild systemic symptoms with low likelihood to find a positive COVID status and good prognosis although the common long-lasting duration. Beyond the cutaneous manifestations secondary to SARS-CoV-2 infection, namely CLL, macular-papular rash, urticaria and vaso-occlusive signs, other cutaneous diseases probably as a consequence of viral reactivation have been reported with major frequency, such as herpes zoster or PR. In particular, a few cases of PR in patients positive to SARS-CoV-2 have been published, 7,8 but the evidence that the two conditions could be related remains scarce. Whether PR could be considered a direct manifestations of COVID-19 or the result of Herpesvirus-6 or 7 (HHV-6 or 7) reactivation is not clear, anyway the occurrence of cases of PR during the pandemic could be underreported. The co-occurrence of CLL and PR has never been reported before and our case is the first one to the best of our knowledge. The exact aetiology of PR is not known yet, even though it is likely to be considered like an immune reaction secondary to HHV-6 or 7 infection or reactivation. It has been recently shown by Drago et al. 8 a concomitant reactivation of HHV-6, HHV-7 and Epstein-Barr Virus during COVID-19, thus demonstrating why PR may appear in these patients. On the other hand, CLL are often found in negative patients and they could be related to an immune reaction, probably mediated by interferon, in young patients with strong response to virus and fast clearance of serum antibodies. 9, 10 Whether the association between PR and CLL could be considered casual or not could be matter of debate, but anyway, the two phenomena, although different in clinical presentation, have in common some features: (i) they usually affect young patients; (ii) no or mild systemic symptoms are seen; (iii) the direct presence of guilty virus is hard to demonstrate; (iv) spontaneous long-lasting resolution. In this particular case, as the patient had a recurrence of CLL after a first episode a few months before, the second occurrence of CLL together with the unusual association with PR could be considered as an immune response following either another contact with SARS-CoV-2 or a reactivation of HHV-6 or 7 in a patient who previously developed immunity against SARS-CoV-2. Our invite to researchers is to observe and describe other patients with this very singular association in order to start further and deeper investigations to better clarify the genesis of this very interesting phenomenon, new for everyone such as all what has happened to health community and people in the world. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients Chilblain-like lesions during the COVID-19 pandemic: should we really worry? Dermoscopy of chilblain-like lesions during the COVID-19 outbreak: a multicenter study on 10 patients Acral findings during the COVID-19 outbreak: Chilblain-like lesions should be preferred to acroischemic lesions Chilblain-like lesions during COVID-19 pandemic: the state of the art Chilblain-like lesions and COVID-19: second wave, second outbreak Pityriasis rosea as a leading manifestation of COVID-19 infection Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19 Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 'The patients in this manuscript have given written informed consent to the publication of their case details'. None. The authors have no financial obligations or conflict of interest to declare.